- Summarize recommended diagnostic techniques for presbyopia
- Analyze the efficacy and safety data associated with new and emerging presbyopia pharmacologic treatments
- Apply strategies to enhance patient quality of life (QoL) following the administration of novel presbyopia therapies
- Identify key clinical features of RVO using advanced imaging techniques
- Understand unmet needs and advances in new therapies for nAMD
- Understand unmet needs and advances in new therapies for DME
- Recognize common challenges in referral practices and their impact on visual outcomes
- Summarize the disease burden in patients with Demodex blepharitis
- Assess objective and subjective clinical findings to establish a diagnosis of Demodex blepharitis
- Implement targeted therapies in treatment plans to eradicate Demodex and improve outcomes in patients with Demodex blepharitis
Featured CIME Symposia
OVERVIEW
Recent advances in the treatment of presbyopia have focused on pharmacological agents as a novel therapeutic strategy that offers noninvasive, reversible options capable of enhancing depth of focus without altering the natural lens structure. As new and emerging pharmacological therapies show potential in restoring near vision through modulation of pupillary dynamics, the mechanisms of action, safety profiles, and durability of effect must be critically evaluated to guide evidence-based treatment decisions. Their implementation in clinical practice necessitates an in-depth understanding of their impact on pupil size, accommodation, and ocular surface health, as well as potential risks such as retinal traction or vitreoretinal complications in predisposed patients.
Given the ongoing refinement of these therapies, clinicians must remain vigilant to the long-term safety and efficacy considerations, especially as new compounds are explored and the pharmacological landscape for presbyopia continues to evolve. This educational symposium featuring expert presentations and discussion will enable a nuanced understanding of the comparative utility of these agents and also foster informed discussions around optimizing outcomes for diverse patient populations, ensuring that the adoption of these treatments is both scientifically grounded and patient centered.
LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
Overview
Neovascular age-related macular degeneration and diabetic macular edema are major drivers of vision loss, which along with retinal vein occlusion (RVO) create substantial patient burdens. In this program, expert faculty will share insights into diagnosing RVO, individualizing extended treatment intervals with newer anti-VEGF therapies, and optimizing communication with patients and within the eye-care team.
Learning Objectives
Upon completion of this activity, participants will be able to:
Overview
Demodex blepharitis can have a significant impact on the quality of life of affected individuals and may cause significant complications if left untreated. A diagnosis can be suspected by the presence of cylindrical dandruff at the base of the eyelash and is confirmed by light microscopy of an epilated lash or by in vivo confocal microscopy.
Until recently, management of Demodex blepharitis often relied on topical tea tree oil or its derivatives, which are frequently associated with ocular burning and irritation. Effective strategies that target the underlying cause of the disease may minimize the clinical burden of disease and risk of complications. Fortunately, lotilaner 0.25% ophthalmic solution, a targeted therapy for the treatment of Demodex blepharitis became available in 2023. In this satellite symposium, expert faculty will review the diagnosis and management of Demodex blepharitis, including review of available and investigational therapies.
Learning Objectives
Upon completion of this activity, participants will be able to: